NCT06666114

Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 232 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This was a retrospective observational study that relied on data extracted from patient chart review at the participating sites. At least 12 months of patient data was verified, comprising at least 6 months (pre-period) and 6 months (post-period) after secukinumab initiation (index date). All data extracted from patient charts was entered into an electronic case report form (eCRF), specifically designed to capture all variables needed for the study data analysis.

Conditions

• Psoriasis (PsO)
• Psoriatic Arthritis (PsA)

Timeline

• Start date: 2021-08-03
• Primary completion: 2023-10-10
• Completion: 2023-10-10
• First posted: 2024-10-30
• Last updated: 2024-10-30

Locations

1 site across 1 country: Brazil